FGL1 (human) ELISA Kit

CHF 690.00
In stock
AG-45B-0022-KI0196 wellsCHF 690.00
NEW
More Information
Product Details
Synonyms Fibrinogen-like Protein 1; FGL-1; Hepatocyte-derived Fibrinogen-related Protein 1; HFREP-1; Hepassocin
Product Type Kit
Properties
Application Set Quantitative ELISA
Specificity

Detects human FGL1 in serum, plasma and cell culture supernatant.

Crossreactivity Human
Quantity

1 x 96 wells

Sensitivity 1.8pg/ml
Range 7.8 to 500pg/ml
Sample Type Cell Culture Supernatant
Plasma
Serum
Assay Type Sandwich
Detection Type Colorimetric
Other Product Data

UniProt link Q08830: FGL1 (human)

Accession Number Q08830
Shipping and Handling
Shipping BLUE ICE
Short Term Storage +4°C
Long Term Storage +4°C
Handling Advice After standard reconstitution, prepare aliquots and store at -20°C.
Avoid freeze/thaw cycles.
Plate and reagents should reach room temperature before use.
Use/Stability 12 months after the day of manufacturing. See expiry date on ELISA Kit box.
Documents
Manual Download PDF
MSDS Download PDF
Product Specification Sheet
Datasheet Download PDF

FGL1 (Fibrinogen-like protein 1; also called Hepatocyte-derived fibrinogen-related protein 1; HFREP-1 or Hepassocin) was initially identified as an overexpressed transcript in hepatocyte carcinoma and as a transcript enriched in regenerating liver. FGL1 is expressed at lower levels in brown and white adipose in the setting of liver injury. A low level expression of FGL1 is also observed in the pancreas. FGL1 is a 34 kDa protein structurally similar to Angiopoietin-like factors 2, 3, 4 and 6, which regulate lipid metabolism and energy utilization. It was proposed that FGL1 is a member of an emerging group of proteins having potential roles in liver metabolism and liver regeneration. Recently, FGL1 has also been shown to be upregulated in human cancers and FGL1 is a major functional ligand of LAG-3. FGL1 interacts with LAG-3 in an MHC-II-independent manner and this interaction involves the FGL1 fibrinogen-like domain and the LAG-3 D1-D2 domain. FGL1-LAG-3 interaction blockade promotes tumor immunity by stimulating T cell expansion and activation. FGL1 forms two disulfide-linked homodimers and also higher molecular weight homooligomers that bind to LAG-3 much better than the dimeric forms. This binding to LAG-3 inhibits T cell responses. FGL1 is normally released by the liver in low levels but at higher levels in certain cancer such as non-small cell lung carcinomas (NSCLC) . Upregulated FGL1 in human cancers is associated with a poor prognosis.

© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.